Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sunshine Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sunshine Biopharma's regulatory disclosures and financial reporting.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,000,000 Common Units of Sunshine Biopharma Inc., representing 5.83% of the class.
The filing states the percentage is based on 16,165,945 Common Units outstanding as referenced from the issuer's prospectus and Form 8-K filings dated May 19, 2026. The filing notes 2,000,000 Series C Warrants exercisable into common stock, which are subject to a 4.99% beneficial ownership limitation. The reporting person is organized in the Cayman Islands and is represented by Directors David Feldman and Joel Arber; the cover signature is by Mr. Feldman.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,000,000 Common Units of Sunshine Biopharma Inc., representing 5.83% of the class.
The filing states the percentage is based on 16,165,945 Common Units outstanding as referenced from the issuer's prospectus and Form 8-K filings dated May 19, 2026. The filing notes 2,000,000 Series C Warrants exercisable into common stock, which are subject to a 4.99% beneficial ownership limitation. The reporting person is organized in the Cayman Islands and is represented by Directors David Feldman and Joel Arber; the cover signature is by Mr. Feldman.
Sunshine Biopharma Inc. Schedule 13G: Reporting persons led by Michael Bigger reported beneficial ownership of 805,000 shares of Common Stock, equal to 4.73% of 17,005,945 shares outstanding as of the issuer prospectus. The filing states the Reporting Persons sold all their Common Stock as of May 19, 2026.
The filing also lists warrants (Pre-Funded, Series B, Series C) that were subject to 4.99% beneficial ownership limitations and were excluded from the reported beneficial ownership counts.
Sunshine Biopharma Inc. Schedule 13G: Reporting persons led by Michael Bigger reported beneficial ownership of 805,000 shares of Common Stock, equal to 4.73% of 17,005,945 shares outstanding as of the issuer prospectus. The filing states the Reporting Persons sold all their Common Stock as of May 19, 2026.
The filing also lists warrants (Pre-Funded, Series B, Series C) that were subject to 4.99% beneficial ownership limitations and were excluded from the reported beneficial ownership counts.
Sunshine Biopharma Inc. completed a best efforts public unit offering, raising approximately $6.0 million in gross proceeds through 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit.
Each unit includes one share of common stock or one Pre-Funded Warrant plus two Series C Warrants, each Series C Warrant exercisable at $0.50 per share for five years. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share until fully exercised. If all Series C Warrants are exercised on a cash basis, the Company could receive up to an additional approximately $12.0 million in gross proceeds.
The Company intends to use net proceeds for general corporate purposes and working capital, supporting its Canadian generic drug portfolio and proprietary programs in liver cancer and SARS-related coronavirus infections.
Sunshine Biopharma Inc. completed a best efforts public unit offering, raising approximately $6.0 million in gross proceeds through 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit.
Each unit includes one share of common stock or one Pre-Funded Warrant plus two Series C Warrants, each Series C Warrant exercisable at $0.50 per share for five years. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share until fully exercised. If all Series C Warrants are exercised on a cash basis, the Company could receive up to an additional approximately $12.0 million in gross proceeds.
The Company intends to use net proceeds for general corporate purposes and working capital, supporting its Canadian generic drug portfolio and proprietary programs in liver cancer and SARS-related coronavirus infections.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sunshine Biopharma Inc. director Natan David received a stock award of 100,000 shares of Common Stock. The shares were granted at a price of $0.00 per share as compensation, not through an open-market purchase. Following this grant, he directly holds 100,000 shares.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sunshine Biopharma Inc. director Natan David received a stock award of 100,000 shares of Common Stock. The shares were granted at a price of $0.00 per share as compensation, not through an open-market purchase. Following this grant, he directly holds 100,000 shares.
Sunshine Biopharma Inc. reported 2025 revenue of $36.3 million, a 4.1% increase from 2024, as it expanded its generic drug portfolio and advanced proprietary R&D programs. Gross profit rose to $12.26 million, while general and administrative expenses increased to $18.48 million, including a non-cash, non-recurring $1.75 million impairment charge on intangible assets.
The company recorded a net loss of $5.98 million for 2025, slightly higher than 2024. It raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion and launched nine new generic prescription drugs. Management implemented cost-reduction initiatives in January 2026, which are expected to lower expenses by about $2 million to $3 million in 2026 as it works toward near-term profitability.
Sunshine Biopharma Inc. reported 2025 revenue of $36.3 million, a 4.1% increase from 2024, as it expanded its generic drug portfolio and advanced proprietary R&D programs. Gross profit rose to $12.26 million, while general and administrative expenses increased to $18.48 million, including a non-cash, non-recurring $1.75 million impairment charge on intangible assets.
The company recorded a net loss of $5.98 million for 2025, slightly higher than 2024. It raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion and launched nine new generic prescription drugs. Management implemented cost-reduction initiatives in January 2026, which are expected to lower expenses by about $2 million to $3 million in 2026 as it works toward near-term profitability.
Sunshine Biopharma Inc. reported 2025 revenue of $36,305,891, up from $34,874,283 in 2024, driven mainly by expanded Canadian generic drug sales through its Nora Pharma subsidiary. Cost of sales was $24,050,214, yielding gross profit of $12,255,677.
The company remains unprofitable, recording a 2025 net loss of $5,975,352 and an accumulated deficit of $75,015,126, though operating cash use declined versus 2024. Sunshine ended 2025 with $9,123,308 in cash and believes this will fund operations for about 18 months. Its portfolio includes 71 generic drugs in Canada, 22 pipeline generics, OTC supplements, and two proprietary programs (K1.1 mRNA for liver cancer and SBFM-PL4, a PLpro inhibitor for SARS coronavirus) in animal testing. In December 2025 it received a USPTO Notice of Allowance for its coronavirus protease inhibitor patent, and it holds trademarks for “Sunshine Biopharma Inc.” in the U.S. and Canada.
Sunshine Biopharma Inc. reported 2025 revenue of $36,305,891, up from $34,874,283 in 2024, driven mainly by expanded Canadian generic drug sales through its Nora Pharma subsidiary. Cost of sales was $24,050,214, yielding gross profit of $12,255,677.
The company remains unprofitable, recording a 2025 net loss of $5,975,352 and an accumulated deficit of $75,015,126, though operating cash use declined versus 2024. Sunshine ended 2025 with $9,123,308 in cash and believes this will fund operations for about 18 months. Its portfolio includes 71 generic drugs in Canada, 22 pipeline generics, OTC supplements, and two proprietary programs (K1.1 mRNA for liver cancer and SBFM-PL4, a PLpro inhibitor for SARS coronavirus) in animal testing. In December 2025 it received a USPTO Notice of Allowance for its coronavirus protease inhibitor patent, and it holds trademarks for “Sunshine Biopharma Inc.” in the U.S. and Canada.
Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. is informing holders that on February 18, 2026 the majority stockholder approved an amendment authorizing the Board to effect, at its discretion, a reverse stock split of up to 1-for-10. The Board may set any whole-number ratio up to 1-for-10 or abandon the action prior to filing.
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of February 18, 2026, there were 4,905,945 shares outstanding; a 1-for-10 split would reduce outstanding shares to 490,595, subject to rounding.
Sunshine Biopharma Inc. is informing holders that on February 18, 2026 the majority stockholder approved an amendment authorizing the Board to effect, at its discretion, a reverse stock split of up to 1-for-10. The Board may set any whole-number ratio up to 1-for-10 or abandon the action prior to filing.
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of February 18, 2026, there were 4,905,945 shares outstanding; a 1-for-10 split would reduce outstanding shares to 490,595, subject to rounding.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.